Repinatrabit
Phenylketonuria
Otsuka Pharmaceutical Development & Commercialization, Inc.Small moleculePhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 58/ 100
- Competitive Position
- 89/ 100
Competitive context
17 Active assets in the Phenylketonuria cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sapropterin Dihydrochloride Sohag University | Phase 4 | A |
Phenylase BioMarin Pharmaceutical | Phase 4 | A |
Ravpal-Peg BioMarin Pharmaceutical | Phase 2 | BB |
Escherichia Coli Strain Synb1618 Synlogic | Phase 2 | BB |
L-Carnitine Mansoura University | Phase 4 | BB |
View all 26 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →